osimertinib + dexamethasone + granulocyte colony stimulating factor

This is a combination regimen consisting of three agents: - **Osimertinib** is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively targets both EGFR-sensitizing and T790M resistance mutations. It is primarily used in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressant properties. In this context, it can be used to reduce inflammation, manage side effects, or as part of regimens to mobilize neutrophils. - **Granulocyte colony stimulating factor (G-CSF)** is a cytokine that stimulates the bone marrow to produce neutrophils and other granulocytes. It is commonly used for neutrophil mobilization in donors for granulocyte transfusion therapy or as supportive care during chemotherapy-induced neutropenia. The combination of dexamethasone and G-CSF has been shown to synergistically increase peripheral blood neutrophil counts in healthy donors, optimizing yields for granulocyte transfusions[1][6][8]. Osimertinib may be combined with these agents either as part of supportive care during cancer therapy or potentially within investigational protocols where enhanced immune support or infection prophylaxis is required.